AMARILLO, TX -- (MARKET WIRE) -- 10/20/05 -- Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it had entered into a licensing and supply agreement with Seattle-based Global Kinetics, Inc. to provide low dose oral interferon for sale in Cambodia, Laos and Vietnam.

Interest in the Company's low dose oral interferon has risen with international concern about the potential of the current bird flu outbreak to develop into a pandemic. Health care professionals agree that the public is vulnerable to the pending influenza pandemic. Effective vaccination for influenza is the goal of health officials. However, no vaccine is yet available for the H5N1 virus (bird flu), and the therapies that do exist, such as Tamiflu, are in limited supply worldwide. Consequently, ABI and Global Kinetics are working together to bring a promising new prevention and treatment option for influenza to the developing world.

Global Kinetics (www.globalkinetics.net) intends to market ABI's low dose oral interferon through a Cambodian company (Global Kinetics of Cambodia). "Low-dose oral interferon represents an inexpensive, non-toxic modulation of the immune system during, or before, influenza infection. Our first purchase order is expected from the Kingdom of Cambodia so a supply of oral interferon will be available in case bird flu infects government personnel. Government officials in Cambodia have reviewed the clinical observations made on thousands of influenza patients in the former Soviet Union, Bulgaria, China, and Japan. These studies indicate that significant clinical benefits occurred in patients given low-dose interferon intranasally or orally during natural outbreaks of influenza," said Global Kinetics President Jerry Frasier. ABI President Joseph Cummins said, "We are pleased to be working with Global Kinetics and look forward to a long lasting and mutually beneficial relationship."

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2004.

Investor Relations:
Philippe Niemetz
WPH Consultants, Ltd.
Tel: 800-477-7570
Tel: 212-344-6464
Fax: 212-618-1276
e-mail: Email Contact

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: 806-376-1741 x 13
Fax: 806-376-9301
e-mail: Email Contact

• Luxury Yachts for Sale in Croatia